Literature DB >> 24786926

Interleukin 18: a biomarker for differential diagnosis between adult-onset Still's disease and sepsis.

Roberta Priori1, Serena Colafrancesco1, Cristiano Alessandri1, Antonina Minniti1, Carlo Perricone1, Giancarlo Iaiani1, Donatella Palazzo1, Guido Valesini2.   

Abstract

OBJECTIVE: The differential diagnosis between rheumatic diseases and infectious conditions is a great challenge in clinical practice. Adult-onset Still's disease (AOSD) is a rare systemic inflammatory syndrome that shares several clinical and laboratory variables with sepsis. Interleukin (IL)-18 is overexpressed in AOSD, suggesting a possible role as a disease biomarker. The aim of our study was to detect IL-18 serum levels in a cohort of patients with AOSD and sepsis and to address its possible role as a biomarker for differential diagnosis.
METHODS: A group of unselected patients with AOSD diagnosed according to the Yamaguchi criteria and consecutive patients with sepsis diagnosed according to the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference criteria were enrolled. The clinical and laboratory data were collected. In the AOSD group, disease activity was assessed by Pouchot's and Rau's criteria. IL-18 serum levels were detected by ELISA.
RESULTS: Thirty-nine patients with AOSD and 18 patients with sepsis were enrolled. Two out of 18 patients with sepsis (11.1%) also fulfilled the Yamaguchi criteria. A significant difference was found in IL-18 serum levels between patients with active and inactive disease (p < 0.001), and it positively correlated with disease activity (p = 0.0003), ferritin serum level (p = 0.016), and erythrocyte sedimentation rate (p = 0.041). IL-18 was significantly increased in patients with AOSD when compared with sepsis (p = 0.014). For a cutoff of 148.9 pg/ml, this test had a specificity of 78.3% and a sensitivity of 88.6%.
CONCLUSION: We have demonstrated that IL-18 can be a biomarker for differential diagnosis between AOSD and sepsis.

Entities:  

Keywords:  ADULT-ONSET STILL’S DISEASE; FERRITIN; INTERLEUKIN 18; SEPSIS

Mesh:

Substances:

Year:  2014        PMID: 24786926     DOI: 10.3899/jrheum.130575

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  23 in total

1.  sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia.

Authors:  S Colafrancesco; R Priori; C Alessandri; E Astorri; C Perricone; M Blank; N Agmon-Levin; Y Shoenfeld; G Valesini
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  [Novel immunodiagnostics for inflammatory arthritis].

Authors:  M Wahle; E Kling
Journal:  Z Rheumatol       Date:  2016-05       Impact factor: 1.372

3.  H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome.

Authors:  P Ruscitti; P Cipriani; P Di Benedetto; V Liakouli; O Berardicurti; F Carubbi; F Ciccia; G Guggino; G Triolo; R Giacomelli
Journal:  Clin Exp Immunol       Date:  2017-10-20       Impact factor: 4.330

4.  Upregulation of circulating microRNA-134 in adult-onset Still's disease and its use as potential biomarker.

Authors:  Tsai-Ling Liao; Yi-Ming Chen; Chia-Wei Hsieh; Hsin-Hua Chen; Hsiu-Chin Lee; Wei-Ting Hung; Kuo-Tung Tang; Der-Yuan Chen
Journal:  Sci Rep       Date:  2017-06-23       Impact factor: 4.379

5.  Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study.

Authors:  Serena Colafrancesco; Roberta Priori; Guido Valesini; Lorenza Argolini; Elena Baldissera; Elena Bartoloni; Daniele Cammelli; Giovanni Canestrari; Luca Cantarini; Elena Cavallaro; Giulio Cavalli; Lucia Cerrito; Paola Cipriani; Lorenzo Dagna; Ginevra De Marchi; Salvatore De Vita; Giacomo Emmi; Gianfranco Ferraccioli; Micol Frassi; Mauro Galeazzi; Roberto Gerli; Roberto Giacomelli; Elisa Gremese; Florenzo Iannone; Giovanni Lapadula; Giuseppe Lopalco; Raffaele Manna; Alessandro Mathieu; Carlomaurizio Montecucco; Marta Mosca; Ilaria Piazza; Matteo Piga; Irene Pontikaki; Micol Romano; Silvia Rossi; Maurizio Rossini; Piero Ruscitti; Elena Silvestri; Chiara Stagnaro; Rosaria Talarico; Angela Tincani; Ombretta Viapiana; Gianfranco Vitiello; Francesca Fabris; Sara Bindoli; Leonardo Punzi; Paola Galozzi; Paolo Sfriso
Journal:  Front Pharmacol       Date:  2017-06-13       Impact factor: 5.810

Review 6.  Adult-Onset Still's Disease: Still a Serious Health Problem (a Case Report and Literature Review).

Authors:  Mojgan Agha-Abbaslou; Ana Maria Bensaci; Oluchi Dike; Mark C Poznansky; Arooj Hyat
Journal:  Am J Case Rep       Date:  2017-02-03

Review 7.  Interleukin-18 as a diagnostic marker of adult-onset Still's disease in older patients: a case report and review of the literature.

Authors:  Daisuke Usuda; Yoshiki Furumura; Kento Takeshima; Ryusho Sangen; Yasuhiro Kawai; Yuji Kasamaki; Yoshitsugu Iinuma; Tsugiyasu Kanda
Journal:  J Med Case Rep       Date:  2018-07-10

8.  Circulating regulatory T cells in adult-onset Still's disease: Focusing on their plasticity and stability.

Authors:  Yasuhiro Shimojima; Takanori Ichikawa; Dai Kishida; Ryota Takamatsu; Yoshiki Sekijima
Journal:  Clin Exp Immunol       Date:  2021-08-12       Impact factor: 4.330

9.  Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.

Authors:  Cem Gabay; Bruno Fautrel; Jürgen Rech; François Spertini; Eugen Feist; Ina Kötter; Eric Hachulla; Jacques Morel; Thierry Schaeverbeke; Mohamed A Hamidou; Thierry Martin; Bernhard Hellmich; Peter Lamprecht; Hendrik Schulze-Koops; Delphine Sophie Courvoisier; Andrew Sleight; Eduardo Jorge Schiffrin
Journal:  Ann Rheum Dis       Date:  2018-02-22       Impact factor: 19.103

10.  Severe Adult-onset Still Disease with Constrictive Pericarditis and Pleuritis That Was Successfully Treated with Tocilizumab in Addition to Corticosteroids and Cyclosporin A.

Authors:  Hoshimi Kawaguchi; Hiroto Tsuboi; Mizuki Yagishita; Toshihiko Terasaki; Mayu Terasaki; Masaru Shimizu; Fumika Honda; Ayako Ohyama; Hiroyuki Takahashi; Haruka Miki; Masahiro Yokosawa; Hiromitsu Asashima; Shinya Hagiwara; Yuya Kondo; Isao Matsumoto; Takayuki Sumida
Journal:  Intern Med       Date:  2017-12-21       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.